One of the most frustrating barriers in cancer immunology is that leukemia cells frequently evade T-cell killing by downregulating MHC molecules — the surface markers that normally flag a cell as cancerous. A new mechanism reported in PNAS suggests this evasion strategy may be circumventable, with significant implications for the treatment of acute myeloid leukemia (AML), one of the most lethal blood cancers.
Researchers demonstrated that cytotoxic T lymphocytes (CTLs) from multiple independent donors can kill AML cells through a pathway that is TCR-dependent yet MHC-independent — meaning the T cell receptor is engaged, but not through the conventional peptide-MHC complex. The key facilitator is CD64, a high-affinity Fc-gamma receptor (FcγRI) constitutively expressed on AML blasts. CD64 appears to act as a bridging molecule, linking antibody-coated targets to the TCR machinery and triggering a cytotoxic response without requiring MHC presentation. The result is a non-classical killing axis that bypasses the primary immune escape route exploited by many AML tumors.
This finding sits at a meaningful intersection of innate and adaptive immune biology. CD64 is typically associated with myeloid cells and has been explored as a diagnostic AML marker, but its role in facilitating T-cell cytotoxicity is a genuinely novel observation. The broader research landscape has long sought mechanisms to restore anti-tumor immunity in MHC-loss tumors, and approaches like CAR-T and bispecific antibodies have partially addressed this — but they rely on engineered cells or exogenous reagents. The CD64-TCR axis described here could be exploitable with conventional T cells and existing antibody therapeutics, potentially widening the therapeutic window. Important caveats apply: the study does not yet demonstrate efficacy in animal models or clinical settings, and the precise molecular details of TCR engagement remain to be fully resolved. This is early-stage but mechanistically significant work that could reshape how AML immunotherapy is engineered.